Novo Nordisk Foundation

Novo Nordisk Foundation

NC State University and the Technical University of Denmark gratefully acknowledge the US$27 million in funding provided by the Novo Nordisk Foundation to enable the AIM-Bio Program. 

The Novo Nordisk Foundation is an independent Danish foundation with corporate interests. It has two objectives: 1) to provide a stable basis for the commercial and research activities of the companies in the Novo Group; and 2) to support scientific, humanitarian and social causes. In accordance with the Foundation’s Articles of Association, the Foundation is obligated to maintain a controlling interest in Novo Nordisk A/S and Novozymes A/S, the Novo Group’s two large publicly listed companies.

The vision of the Foundation is to contribute significantly to research and development that improves the lives of people and the sustainability of society. Since 2010, the Foundation has donated more than DKK 25 billion (USD 4 billion), primarily for research at public institutions and hospitals in Denmark and the other Nordic countries as well as research-based treatment and prevention of diabetes. Within the biotech area, the Foundation supports research of the highest excellence, education and training in the study and use of biological systems and processes for industrial, agricultural and environmental purposes. The objective is to support life science solutions benefiting people and the environment.

Read more at www.novonordiskfonden.dk/en

Novo Nordisk and Novozymes

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. Novozymes is world leading in biological solutions, in particular industrial enzymes and microorganisms. Both companies are headquartered in Denmark but have research, development and production facilities worldwide. In North Carolina, Novo Nordisk operates a major filling facility for insulin and a facility for manufacturing of active pharmaceutical ingredients, both in Clayton. Novozymes North America is headquartered and operates a major facility for enzyme production in Franklinton, NC. Representatives from both Novo Nordisk and Novozymes serve as BTEC’s Advisory Board.